Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Preabsorption of sera with cytomegalovirus (CMV) glycoprotein B (gB) prior to testing for CMV IgG antibody was evaluated for detection of CMV infection during CMV gB vaccine clinical trials. Although, 98.2% of 109 CMV gB vaccine recipients were seropositive with a standard assay, preabsorption of sera with gB reduced their CMV antibody to extremely low levels compared with subjects with CMV infection. One subject who acquired CMV during a vaccine trial was easily identified by gB-absorbed CMV IgG results. The gB-absorbed CMV IgG antibody assay is a promising approach for screening CMV gB vaccine trial participants for CMV infection.
Zhang
Changpin
C
Department of Pediatrics, UAB School of Medicine, Children's Hospital CHB 309, 1600 7th Avenue South, Birmingham, AL 35233, USA.
Pass
Robert F
RF
D000042:Absorption; D000407:Alabama; D000914:Antibodies, Viral / Q000097:blood*; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D022482:Cytomegalovirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007118:Immunoassay; D007074:Immunoglobulin G / Q000097:blood; D010043:Outcome and Process Assessment, Health Care; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D022482:Cytomegalovirus Vaccines; D007074:Immunoglobulin G; D022223:Vaccines, Subunit; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus